GlassScriptPhysician profile
John Mather Davitt
NPI 1730576927
$45,043.74
in general payments reported to CMS, 2019-2025
27 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2021: $259 · 2022: $3,308 · 2023: $11K · 2024: $19K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $34K · Food and Beverage: $4,224 · Travel and Lodging: $3,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $33,500.00 |
| Food and Beverage | $4,223.94 |
| Travel and Lodging | $3,440.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $40,952.66 | 2022-2025 | Da Vinci Surgical System |
| Applied Medical Resources Corporation | $863.90 | 2022-2025 | |
| Hologic Sales and Service, LLC | $644.17 | 2022-2025 | Acessa Provu System, Sonata Sonography-Guided Transcervical Fibroid Ablation System, Novasure |
| Sumitomo Pharma America, INC. | $490.20 | 2023-2025 | Myfembree |
| Caldera Medical, INC | $409.38 | 2022-2024 | Desara |
| Gynesonics, INC. | $236.09 | 2021-2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Coloplast Corp | $206.31 | 2023-2025 | Titan |
| Abbvie INC. | $190.33 | 2019-2024 | Orilissa, Lo Loestrin Fe, Oriahnn |
| Channel Medsystems, INC. | $135.75 | 2023 | |
| Meditrina | $126.60 | 2025 | |
| Therapeuticsmd, INC. | $117.90 | 2019 | |
| Becton, Dickinson and Company | $104.95 | 2025 | |
| Momentis Surgical INC. | $92.91 | 2021 | |
| Covidien LP | $68.61 | 2019 | |
| Depuy Synthes Sales INC. | $59.78 | 2025 | Truespan Orthocord, Milagro |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $53.01 | 2021-2023 | |
| Baxter Healthcare | $45.52 | 2024 | Floseal |
| Astellas Pharma US INC | $44.52 | 2023-2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $30.99 | 2023 | Seglentis |
| Organon LLC | $28.04 | 2023 | Nexplanon |
| Olympus America INC. | $27.87 | 2023 | Olympus |
| Pfizer INC. | $27.11 | 2024 | |
| Smith+Nephew, INC. | $22.64 | 2024 | Stravix Pl |
| Boston Scientific Corporation | $20.29 | 2024 | Upsylon |
| Femselect INC. | $16.27 | 2025 | Enplace |
| Millicent US INC | $14.41 | 2024 | Intrarosa, Femring |
| Exeltis, USA INC. | $13.53 | 2023 | Slynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Davitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.